{"schema_version":"secwatch.filing_event.v1","accession":"0001847367-25-000048","form_type":"8-K","ticker":"ALMS","cik":"0001847367","company_name":"ALUMIS INC.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.788356+00:00","generated_at":"2026-05-16T20:33:35.447420+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alumis Q3 net loss $110.8M; cash $377.7M; Phase 3 psoriasis data expected Q1 2026","bullets":["Net loss of $110.8M for Q3 2025 vs. $93.1M in Q3 2024; R&D expenses rose to $97.8M from $87.8M.","Cash, cash equivalents and marketable securities totaled $377.7M as of September 30, 2025.","Topline Phase 3 ONWARD data for envudeucitinib in plaque psoriasis expected early Q1 2026; Phase 2b SLE data in Q3 2026.","Collaboration revenue of $2.1M from Kaken Pharmaceutical in Q3 2025.","Company expects existing cash to fund pipeline and operations into 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001847367-25-000048","json":"https://secwatch.observer/filing/0001847367-25-000048.json","markdown":"https://secwatch.observer/filing/0001847367-25-000048.md","text":"https://secwatch.observer/filing/0001847367-25-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000048/0001847367-25-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000048/alms-20251113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:33:35.447420+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}